Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Phan Website

Giao Q. Phan, M.D., F.A.C.S.

Selected Publications

1)  Phan GQ, Rosenberg SA.
Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Cancer Control. 20: 289-97, 2013.
2)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
3)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
J. Clin. Oncol. 31: 2152-9, 2013.
4)  Nilubol N, Weisbrod AB, Weinstein LS, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E.
Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy.
World J Surg. 37: 1966-72, 2013.
5)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
6)  Buck CB, Phan GQ, Raiji MT, Murphy PM, McDermott DH, McBride AA.
Complete genome sequence of a tenth human polyomavirus.
J. Virol. 86: 10887, 2012.
7)  Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Clin. Cancer Res. 18: 2039-47, 2012.
8)  Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E.
Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?.
World J Surg. 36: 1368-74, 2012.
9)  Inchauste SM, Lanier BJ, Libutti SK, Phan GQ, Nilubol N, Steinberg SM, Kebebew E, Hughes MS.
Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors.
World J Surg. 36: 1517-26, 2012.
10)  Yavuz S, Simonds WF, Weinstein LS, Collins MT, Kebebew E, Nilubol N, Phan GQ, Libutti SK, Remaley AT, Van Deventer M, Marx SJ.
Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor.
J. Clin. Endocrinol. Metab. 97: 1834-41, 2012.
11)  Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ.
von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms.
Surgery. 152: 1106-17, 2012.
12)  Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
Surgery. 150: 1122-8, 2011.
13)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2011.
14)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011.
15)  Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.
CD8+ enriched.
Clin. Cancer Res. 16: 6122-31, 2010.
16)  Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E.
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease.
J. Am. Coll. Surg. 211: 384-90, 2010.
17)  Phan GQ, Messina JL, Sondak VK, Zager JS.
Sentinel lymph node biopsy for melanoma: indications and rationale.
Cancer Control. 16: 234-9, 2009.
18)  Phan GQ, Weber JS, Sondak VK.
CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Ann. Surg. Oncol. 15: 3014-21, 2008.
19)  Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA.
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Ann. Surg. Oncol. 12: 1005-16, 2005.
20)  Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
J. Clin. Oncol. 23: 6043-53, 2005.
21)  Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc. Natl. Acad. Sci. U.S.A. 100: 8372-7, 2003.
22)  Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
J. Immunother. 26: 349-56, 2003.
23)  Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA.
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
J. Clin. Oncol. 19: 3477-82, 2001.
24)  Phan GQ, Wang E, Marincola FM.
T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.
Expert opinion on biological therapy. 1: 511-23, 2001.
25)  Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL.
Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients.
J. Gastrointest. Surg. 2: 472-82, 1998.
26)  Phan GQ, Yeo CJ, Cameron JL, Maher MM, Hruban RH, Udelsman R.
Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients.
Surgery. 122: 989-96; discussion, 996-7, 1997.
27)  Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR, Bartlett DL.
Targeting vaccinia to solid tumors with local hyperthermia.
Hum. Gene Ther. 16: 435-44, 2005.
28)  Wang E, Phan GQ, Marincola FM.
T-cell-directed cancer vaccines: the melanoma model.
Expert opinion on biological therapy. 1: 277-90, 2001.
29)  Mocellin S, Fetsch P, Abati A, Phan GQ, Wang E, Provenzano M, Stroncek D, Rosenberg SA, Marincola FM.
Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
J. Immunother. 24: 447-58, 2002.
30)  Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM.
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration.
Genome Biol. 3: RESEARCH0035, 2002.
31)  Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM.
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2.
J. Immunother. 24: 188-192, 2001.
32)  Bettinotti MP, Panelli MC, Ruppe E, Mocellin S, Phan GQ, White DE, Marincola FM.
Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
Int. J. Cancer. 105: 210-6, 2003.
33)  Attia P, Phan GQ, Duray PH, Rosenberg SA.
Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review.
Am. J. Clin. Oncol. 26: 42-5, 2003.
34)  Phan GQ, Heitmiller RF.
Intramural esophageal dissection.
Ann. Thorac. Surg. 63: 1785-6, 1997.
35)  Ying-zi X, Phan G, Yakushijin K, Horne D.
A synthesis of (+/-) hymenin.
Tetrahedron Letters. 35: 351-354, 1994.
36)  Phan G, Vaughann A, Aft R.
Breast Diseases. In: The Washington Manual of Surgery. Volume Fifth Edition.
Philadelphia: Lippincott Williams & Wilkins; 2008. p. 453-470 [Book Chapter]
Click Here to View Collapsed Bibliography.

This page was last updated on 12/6/2013.